Answers are grounded in this paper and cite their sources.
Liver-targeted gene transfer using vectors based on adeno-associated virus (AAV) has been successfully used to treat several animal models of genetic and acquired disease. Attractive features of AAV vectors include relatively weak activation of the innate immune system and the ability to direct high levels of gene transfer and long-term expression upon in vivo delivery to relatively quiescent cell types, such as hepatocytes. Nonetheless, clinical progress has been slow. Thus far, two phase I/II trials have been performed, both using factor IX gene transfer to the livers of adult male patients with severe hemophilia B.
No takes yet. Share an insight, caveat, or question.
Herzog et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: